IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Markkula, Andrea ^a   Simonsson, Maria ^a   Ingvar, Christian ^a   Rose, Carsten ^a   Jernström, Helena ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Chemotherapy; IL6; Oestrogen receptor; Radiotherapy; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; ESTROGEN RECEPTOR; GENOMIC DNA; INTERLEUKIN 6; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL FEATURE; COHORT ANALYSIS; DEPRESSION; DIPLOTYPE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; ALLELE; BREAST NEOPLASMS; CANCER STAGING; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84908067681     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-759     Document Type: Article

References (50)

1. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012, 36:237-248. 10.1016/j.canep.2012.02.007, 22459198.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
3. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007, 102:129-135. 10.1007/s10549-006-9328-3, 16927176.
4. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003, 103:642-646. 10.1002/ijc.10833, 12494472.
5. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999, 19:1427-1432.
6. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8:887-899. 10.1038/nrc2507, 18846100.
7. Purohit A, Reed MJ. Regulation of estrogen synthesis in postmenopausal women. Steroids 2002, 67:979-983. 10.1016/S0039-128X(02)00046-6, 12398994.
8. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res 2009, 69:4184-4191. 10.1158/0008-5472.CAN-08-2989, 19435922.
9. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007, 16:747-755. 10.1158/1055-9965.EPI-06-0667, 17416766.
10. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B. Interleukin-6-174G-C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003, 63:8051-8056.
11. Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 2013, 31:1656-1661. 10.1200/JCO.2012.46.2143, 3635681, 23530106.
12. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004, 90:419-422. 10.1038/sj.bjc.6601545, 2409577, 14735187.
13. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, Nightingale P, Kitas GD. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009, 204:178-183. 10.1016/j.atherosclerosis.2008.08.036, 18848327.
14. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE. Interleukin-6 gene -174 g > c and -572 g > c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001, 21:1458-1463. 10.1161/hq0901.094280, 11557672.
15. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, Powell JT. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265. 10.1161/01.CIR.103.18.2260, 11342474.
16. Huang M, Wang L, Ma H, Wang J, Xiang M. Lack of an association between interleukin-6-174G/C polymorphism and circulating interleukin-6 levels in normal population: a meta-analysis. DNA Cell Biol 2013, 32:654-664. 10.1089/dna.2013.2148, 24044580.
17. Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A 2010, 107:5681-5686. 10.1073/pnas.0911515107, 2851818, 20176930.
18. Falagas ME, Zarkadoulia EA, Ioannidou EN, Peppas G, Christodoulou C, Rafailidis PI. The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast cancer research : BCR 2007, 9:R44. 10.1186/bcr1744, 2206717, 17640330.
19. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379. 10.1016/S0893-133X(99)00134-7, 10700656.
20. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 2008, 112:197-201. 10.1007/s10549-007-9841-z, 18064563.
21. Illman J, Corringham R, Robinson D, Davis HM, Rossi JF, Cella D, Trikha M. Are inflammatory cytokines the common link between cancer-associated cachexia and depression?. J Support Oncol 2005, 3:37-50.
22. Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernström H. Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 2011, 105:1676-1683. 10.1038/bjc.2011.441, 3242599, 22033271.
23. Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, Jernström H. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer Causes Control 2013, 24:929-940. 10.1007/s10552-013-0169-1, 23412805.
24. Ringberg A, Bågeman E, Rose C, Ingvar C, Jernström H. Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 2006, 119:2242-2243. author reply 2244, 10.1002/ijc.22104, 16841335.
25. WHO Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995, 854:1-452. WHO.
26. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993, 88:791-804. 10.1111/j.1360-0443.1993.tb02093.x, 8329970.
27. Markkula A, Bromee A, Henningson M, Hietala M, Ringberg A, Ingvar C, Rose C, Jernström H. Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes Control 2012, 23:1307-1316. 10.1007/s10552-012-0008-9, 22695757.
28. Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernström H. Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phila) 2012, 5:735-745. 10.1158/1940-6207.CAPR-11-0442, 22401981.
29. Jernström H, Bågeman E, Rose C, Jönsson PE, Ingvar C. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009, 101:1817-1823. 10.1038/sj.bjc.6605428, 2788256, 19935798.
30. Bågeman E, Ingvar C, Rose C, Jernström H. Coffee consumption and CYP1A2*1 F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2008, 17:895-901. 10.1158/1055-9965.EPI-07-0555, 18398030.
31. PS: Power and Sample Size Calculation version 3.0. 2009, [http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize].
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391. 10.1038/sj.bjc.6602678, 2361579, 16106245.
33. Cole SW, Arevalo JM, Manu K, Telzer EH, Kiang L, Bower JE, Irwin MR, Fuligni AJ. Antagonistic pleiotropy at the human IL6 promoter confers genetic resilience to the pro-inflammatory effects of adverse social conditions in adolescence. Dev Psychol 2011, 47:1173-1180. 3592928, 21639625.
34. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6-174G > C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002, 22:599-604. 10.1161/01.ATV.0000013283.84306.1A, 11950697.
35. Khankhanian P, Baranzini SE, Johnson BA, Madireddy L, Nickles D, Croen LA, Wu YW. Sequencing of the IL6 gene in a case-control study of cerebral palsy in children. BMC Med Genet 2013, 14:126. 10.1186/1471-2350-14-126, 3881497, 24314052.
36. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 2783826, 19878981.
37. Shostak K, Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 2011, 13:214. 10.1186/bcr2886, 3236328, 21867572.
38. Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E, Matsuda H, Tanaka A. Nuclear factor-kB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep 2014, 4:4057. 3925966, 24531845.
39. Smith AK, Conneely KN, Pace TW, Mister D, Felger JC, Kilaru V, Akel MJ, Vertino PM, Miller AH, Torres MA. Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun 2014, 38:227-236.
40. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002, 64:883-888. 10.1016/S0006-2952(02)01154-1, 12213582.
41. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumour therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-417. 10.1038/7410, 10202930.
42. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419-1426. 10.1200/JCO.2007.14.5565, 18285604.
43. Schaue D, McBride WH. Links between innate immunity and normal tissue radiobiology. Radiat Res 2010, 173:406-417. 10.1667/RR1931.1, 2865470, 20334512.
44. Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Frontiers in oncology 2012, 2:58. 3366472, 22675673.
45. Borgquist S, Hjertberg M, Henningson M, Ingvar C, Rose C, Jernström H. Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms. Breast Cancer Res Treat 2013, 137:849-862. 10.1007/s10549-012-2367-z, 23274843.
46. Kwan ML, John EM, Caan BJ, Lee VS, Bernstein L, Cheng I, Gomez SL, Henderson BE, Keegan TH, Kurian AW, Lu Y, Monroe KR, Roh JM, Shariff-Marco S, Sposto R, Vigen C, Wu AH. Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. Am J Epidemiol 2014, 179:95-111. 10.1093/aje/kwt233, 24107615.
47. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic Inflammation, and breast cancer. BioFactors (Oxford, England) 2014, 40:1-12.
48. Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H. Impact of COX2 genotype, ER-status, and body constitution on risk of early events in different treatment groups of breast cancer patients. Int J Cancer 2014, 135:1898-1910. 10.1002/ijc.28831, 24599585.
49. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008, 30:112-126. 10.1016/j.genhosppsych.2007.10.008, 18291293.
50. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care 2010, 13:541-547. 10.1097/MCO.0b013e32833cf3bc, 2955626, 20657280.